Investor Relations

Boston Therapeutics Elects Dr. Henry Esber to Its Board of Directors

Download PDF

MANCHESTER, NH--(Marketwire - Dec 22, 2011) - Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the election of Dr. Henry J. Esber to its Board of Directors, effective December 20, 2011.

"We are very pleased to have Dr. Esber join our Board of Directors," said David Platt, Ph.D., Chairman of the Board of Directors and Chief Executive Officer of Boston Therapeutics. "Dr. Esber is a highly regarded executive with extensive drug development and business experience. His expertise is a great addition to the Board of Directors."

"I believe Boston Therapeutics offers the potential to be the leader in diabetes drug development," said Dr. Esber. "I am excited to be a part of a team that has a business model which includes near term revenue through sales of over-the-counter products, such as SUGARDOWN™, while developing PAZ320 as a pharmaceutical candidate for management of post-meal blood glucose in diabetics."

About Henry Esber

Henry J. Esber, Ph.D. has been a Principal in Esber D&D consulting since 2005. From 2003 to 2005, Dr. Esber was a Senior Consultant, Business Development at Charles River Labs, Discovery and Development Services. From 2005 to 2006, Dr. Esber was a consultant and from 2006, he was Senior Vice President and Chief Business Officer for Bio-Quant. Dr. Esber is the co-founder of BioSignature Diagnostics, Inc. and Advanced Drug Delivery, Inc. He serves on the Scientific Advisory Boards of several biotechnology companies and is the author of more than 130 technical publications. Dr. Esber has more than 25 years of experience in the areas of oncology/tumor immunology and immunotherapy as well as strong knowledge in the field of toxicology and regulatory affairs. Dr. Esber received a B.S. degree in biology/pre-med from the College of William and Mary, an M.S. degree in public health and parasitology from the University of North Carolina, and a Ph.D. in immunology/microbiology from West Virginia University Medical Center. Dr. Esber was previously a Director of the Company from September 2009 through December 2010.


SUGARDOWN™, a dietary supplement, is a complex carbohydrate-based chewable tablet to moderate post-meal blood glucose for those concerned about their blood glucose levels. It is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal system to block the action of carbohydrate-hydrolyzing enzymes which break down carbohydrates into simple sugars. SUGARDOWN™ is commercially available at

About PAZ320

PAZ320, a drug candidate currently in clinical study at Dartmouth-Hitchcock Medical Center in New Hampshire to evaluate the efficacy of PAZ320 when added to oral diabetes agents or insulin, is a chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. It is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal system to block the action of carbohydrate-hydrolyzing enzymes which break down carbohydrates into simple sugars. The Dartmouth study population consists of adults aged 18-75 years with Type 2 diabetes, either on oral agents or insulin with a BMI of 25-40 kg/m2 and with HbA1c equal to or less than 9.0%.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, is a leader in the field of glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: PAZ320, a chewable therapeutic compound designed to reduce post-meal glucose excursion, SUGARDOWN™, a chewable complex carbohydrate-based dietary supplement designed to moderate post-meal blood glucose, and IPOXYN, a complex carbohydrate-based oxygen therapeutic administered intravenously for limb ischemia. Earlier this year Boston Therapeutics petitioned the U.S. FDA to submit an Abbreviated New Drug Application (ANDA) for chewable Metformin. The Company signed a licensing agreement with Hong Kong-based Advance Pharmaceuticals Co Ltd. to market SUGARDOWN™ in China. The Company's drug candidate PAZ320 is currently in clinical trials at Dartmouth-Hitchcock Medical Center in N.H.

Boston Therapeutics is headquartered in Manchester, NH

Additional information is available at

SUGARDOWN™ and IPOXYN™ are registered trademarks of Boston Therapeutics, Inc.